C5a alters blood-brain barrier integrity in experimental lupus

FASEB Journal

Volumn 24, Issue 6, 2010, Pages 1682-1688

  Jacob, Alexander ^a   Hack, Bradley ^a   Chiang, Eddie ^a   Garcia, Joe G N ^a   Quigg, Richard J ^a   Alexander, Jessy J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Complement system; Endothelium; Neurodegeneration; Systemic lupus erythematosus

Indexed keywords

ACTIN; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; G PROTEIN COUPLED RECEPTOR; IMMUNOGLOBULIN G; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CYTOSKELETON; ELECTRIC RESISTANCE; ENDOTHELIUM CELL; LUPUS VULGARIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULARIZATION;

ANIMALS; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; BRAIN; CELLS, CULTURED; COMPLEMENT ACTIVATION; COMPLEMENT C5A; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED C57BL; MICE, INBRED MRL LPR; NITRIC OXIDE SYNTHASE TYPE II; REACTIVE OXYGEN SPECIES; RECEPTOR, ANAPHYLATOXIN C5A; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION;

MUS;

EID: 77953522365     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.09-138834     Document Type: Article

References (74)

1. Boumpas, D. T., Fessler, B. J., Austin, H. A., III, Balow, J. E., Klippel, J. H., and Lockshin, M. D. (1995) Systemic lupus erythematosus: emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann. Intern. Med. 123, 42-53
2. Boumpas, D. T., Austin, H. A., III, Fessler, B. J., Balow, J. E., Klippel, J. H., and Lockshin, M. D. (1995) Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann. Intern. Med. 122, 940-950
3. Carroll, M. C. (1998) The lupus paradox. Nat. Genet. 19, 3-4
4. Abel, T., Gladman, D. D., and Urowitz, M. B. (1980) Neuropsychiatric lupus. J. Rheumatol. 7, 325-333
5. Appenzeller, S., Rondina, J. M., Li, L. M., Costallat, L. T., and Cendes, F. (2005) Cerebral and corpus callosum atrophy in systemic lupus erythematosus. Arthritis Rheum. 52, 2783-2789
6. Brey, R. L., Holliday, S. L., Saklad, A. R., Navarrete, M. G., Hermosillo-Romo, D., Stallworth, C. L., Valdez, C. R., Escalante, A., del Rincón, I., Gronseth, G., Rhine, C. B., Padilla, P.,and McGlasson, D. (2002) Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 58, 1214-1220
7. Denburg, J. A., Denburg, S. D., Carbotte, R. M., Long, A. A., and Hanly, J. G. (1988) Nervous system involvement in systemic lupus erythematosus. Israel J. Med. Sci. 24, 754-758
8. Diamond, B., and Volpe, B. (2003) On the track of neuropsychiatric lupus. Arthritis Rheum. 48, 2710-2712
9. Huerta, P. T., Kowal, C., DeGiorgio, L. A., Volpe, B. T., and Diamond, B. (2006) Immunity and behavior: antibodies alter emotion. Proc. Natl. Acad. Sci. U. S. A. 103, 678-683
10. Hughes, G. R. (1988) Systemic lupus erythematosus. Postgrad. Med. J. 64, 517-521
11. Barnum, S. R. (2002) Complement in central nervous system inflammation. Immunol. Res. 26, 7-13 (Pubitemid 35177479)
12. Muller-Eberhard, H. J., and Schreiber, R. D. (1980) Molecular biology and chemistry of the alternative pathway of complement. Adv. Immunol. 29, 1-53
13. Muller-Eberhard, H. J. (1988) Molecular organization and function of the complement system. Annu. Rev. Biochem. 57, 321-347
14. Carroll, M. C., and Fischer, M. B. (1997) Complement and the immune response. Curr. Opin. Immunol. 9, 64-69
15. Daha, M. R., van Kooten, C., and Roos, A. (2006) Compliments from complement: A fourth pathway of complement activation? Nephrol. Dial. Transpl. 21, 3374-3376
16. Farkas, I., Takahashi, M., Fukuda, A., Yamamoto, N., Akatsu, H., Baranyi, L., Tateyama, H., Yamamoto, T., Okada, N., and Okada, H. (2003) Complement C5a receptor-mediated signaling may be involved in neurodegeneration in Alzheimer's disease. J. Immunol. 170, 5764-5771
17. Flierl, M. A., Stahel, P. F., Rittirsch, D., Huber-Lang, M., Niederbichler, A. D., Hoesel, L. M., Touban, B. M., Morgan, S. J., Smith, W. R., Ward, P. A., and Ipaktchi, K. (2009) Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis. Crit. Care 13, R12
18. Moller, T., Nolte, C., Burger, R., Verkhratsky, A., and Kettenmann, H. (1997) Mechanisms of C5a and C3a complement fragment-induced [Ca2+]i signaling in mouse microglia. J. Neurosci. 17, 615-624 (Pubitemid 27024574)
19. Sayah, S., Jauneau, A. C., Patte, C., Tonon, M. C., Vaudry, H., and Fontaine, M. (2003) Two different transduction pathways are activated by C3a and C5a anaphylatoxins on astrocytes. Mol. Brain Res. 112, 53-60
20. Woodruff, T. M., Crane, J. W., Proctor, L. M., Buller, K. M., Shek, A. B., de Vos, K., Pollitt, S., Williams, H. M., Shiels, I. A., Monk, P. N., and Taylor, S. M. (2006) Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB J. 20, 1407-1417
21. Mukherjee, P., and Pasinetti, G. M. (2001) Complement anaphylatoxin C5a neuroprotects through mitogen-activated protein kinase-dependent inhibition of caspase 3. J. Neurochem. 77, 43-49
22. Nishiura, H., Nonaka, H., Revollo, I. S., Semba, U., Li, Y., Ota, Y., Irie, A., Harada, K., Kehrl, J. H., and Yamamoto, T. (2009) Pro- and anti-apoptotic dual functions of the C5a receptor: involvement of regulator of G protein signaling 3 and extracellular signal-regulated kinase. Lab. Invest. 89, 676-694
23. Belmont, H. M., Hopkins, P., Edelson, H. S., Kaplan, H. B., Ludewig, R., Weissmann, G., and Abramson, S. (1986) Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease. Arthritis Rheum. 29, 1085-1089 (Pubitemid 16017798)
24. Hopkins, P., Belmont, H. M., Buyon, J., Philips, M., Weissmann, G., and Abramson, S. B. (1988) Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum. 31, 632-641
25. Alexander, J. J., Zwingmann, C., and Quigg, R. (2005) MRL/lpr mice have alterations in brain metabolism as shown with [(1)H-(13)C] NMR spectroscopy. Neurochem. Int. 47, 143-151
26. Alexander, J. J., Jacob, A., Bao, L., MacDonald, R. L., and Quigg, R. J. (2005) Complement-dependent apoptosis and inflammatory gene changes in murine lupus cerebritis. J. Immunol. 175, 8312-8319 (Pubitemid 41798397)
27. Alexander, J. J., Jacob, A., Vezina, P., Sekine, H., Gilkeson, G. S., and Quigg, R. J. (2007) Absence of functional alternative complement pathway alleviates lupus cerebritis. Eur. J. Immunol. 37, 1691-1701
28. Alexander, J. J., Bao, L., Jacob, A., Kraus, D. M., Holers, V. M., and Quigg, R. J. (2003) Administration of the soluble complement inhibitor, Crry-Ig, reduces inflammation and aquaporin 4 expression in lupus cerebritis. Biochim. Biophys. Acta 1639, 169-176
29. Abbott, N. J., Mendonca, L. L., and Dolman, D. E. (2003) The blood-brain barrier in systemic lupus erythematosus. Lupus 12, 908-915
30. Davson, H., Zlokovic, B. V., Rakic, L., and Segal, M. B. (1993) An Introduction to the Blood-Brain Barrier. Macmillan, London.
31. Davson, H., and Segal, M. B. (1995) Physiology of the CSF and the Blood-Brain Barrier. CRC, New York, New York, USA
32. Ma, X., Foster, J., and Sakic, B. (2006) Distribution and prevalence of leukocyte phenotypes in brains of lupus-prone mice. J. Neuroimmunol. 179, 26-36
33. James, W. G., Hutchinson, P., Bullard, D. C., and Hickey, M. J. (2006) Cerebral leucocyte infiltration in lupus-prone MRL/ MpJ-fas lpr mice - roles of intercellular adhesion molecule-1 and P-selectin. Clin. Exp. Immunol. 144, 299-308
34. Vogelweid, C. M., Johnson, G. C., Besch-Williford, C. L., Basler, J., and Walker, S. E. (1991) Inflammatory central nervous system disease in lupus-prone MRL/lpr mice: comparative histologic and immunohistochemical findings. J. Neuroimmunol. 35, 89-99
35. Rice, A., Liu, Y., Michaelis, M. L., Himes, R. H., Georg, G. I., and Audus, K. L. (2005) Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the blood-brain barrier in vitro and in situ. J. Med. Chem. 48, 832-838
36. Hanly, J. G., Robichaud, J., and Fisk, J. D. (2006) Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. J. Rheumatol. 33, 1553-1558 (Pubitemid 44168826)
37. DeGiorgio, L. A., Konstantinov, K. N., Lee, S. C., Hardin, J. A., Volpe, B. T., and Diamond, B. (2001) A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat. Med. 7, 1189-1193
38. Quigg, R. J., Lo, C. F., Alexander, J. J., Sneed, A. E., III, and Moxley, G. (1995) Molecular characterization of rat Crry: wide-spread distribution of two alternative forms of Crry mRNA. Immunogenetics 42, 362-367
39. Gotze, O., and Muller-Eberhard, H. J. (1976) The alternative pathway of complement activation. Adv. Immunol. 24, 1-35
40. Carroll, M. C. (1998) The role of complement and complement receptors in induction and regulation of Immunity Annu. Rev. Immunol. 16, 545-568
41. Hahn, B. H. (2001) Lessons in lupus: the mighty mouse. Lupus 10, 589-593
42. Ballok, D. A. (2007) Neuroimmunopathology in a murine model of neuropsychiatric lupus. Brain Res. Rev. 54, 67-79
43. Alexander, J. J., and Quigg, R. J. (2007) Systemic lupus erythematosus and the brain: what mice are telling us. Neurochem. Int. 50, 5-11
44. Ballok, D. A., Szechtman, H., and Sakic, B. (2003) Taste responsiveness and diet preference in autoimmune MRL mice. Behav. Brain Res. 140, 119-130
45. Hess, D. C., Taormina, M., Thompson, J., Sethi, K. D., Diamond, B., Rao, R., Chamberlain, C. R., and Feldman, D. S. (1993) Cognitive and neurologic deficits in the MRL/lpr mouse: a clinicopathologic study. J. Rheumatol. 20, 610-617 (Pubitemid 23138846)
46. Farrell, M., Sakic, B., Szechtman, H., and Denburg, J. A. (1997) Effect of cyclophosphamide on leukocytic infiltration in the brain of MRL/lpr mice. Lupus 6, 268-274 (Pubitemid 27160647)
47. Sakic, B., Denburg, J. A., Denburg, S. D., and Szechtman, H. (1996) Blunted sensitivity to sucrose in autoimmune MRL-lpr mice: a curve-shift study. Brain Res. Bull. 41, 305-311
48. Szechtman, H., Sakic, B., and Denburg, J. A. (1997) Behaviour of MRL mice: an animal model of disturbed behaviour in systemic autoimmune disease. Lupus 6, 223-229 (Pubitemid 27160639)
49. Ballok, D. A., Woulfe, J., Sur, M., Cyr, M., and Sakic, B. (2004) Hippocampal damage in mouse and human forms of systemic autoimmune disease. Hippocampus 14, 649-661
50. Theofilopoulos, A. N., Kofler, R., Singer, P. A., and Dixon, F. J. (1989) Molecular genetics of murine lupus models. Adv. Immunol. 46, 61-109 (Pubitemid 19254749)
51. Theofilopoulos, A. N., and Dixon, F. J. (1985) Murine models of systemic lupus erythematosus. Adv. Immunol. 37, 269-390
52. Dixon, F. J., Andrews, B. S., Eisenberg, R. A., McConahey, P. J., Theofilopoulos, A. N., and Wilson, C. B. (1978) Etiology and pathogenesis of a spontaneous lupus-like syndrome in mice. Arthritis Rheum. 21, S64-S67
53. Brown, R. C., Morris, A. P., and O'Neil, R. G. (2007) Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells. Brain Res. 1130, 17-30
54. Coisne, C., Dehouck, L., Faveeuw, C., Delplace, Y., Miller, F., Landry, C., Morissette, C., Fenart, L., Cecchelli, R., Tremblay, P., and Dehouck, B. (2005) Mouse syngenic in vitro blood-brain barrier model: a new tool to examine inflammatory events in cerebral endothelium. Lab. Invest. 85, 734-746
55. Borbiev, T., Birukova, A., Liu, F., Nurmukhambetova, S., Gerthoffer, W. T., Garcia, J. G., and Verin, A. D. (2004) p38 MAP kinase-dependent regulation of endothelial cell permeability. Am. J. Physiol. Lung Cell. Mol. Physiol. 287, L911-L918
56. Dudek, S. M., and Garcia, J. G. (2001) Cytoskeletal regulation of pulmonary vascular permeability. J. Appl. Physiol. 91, 1487-1500
57. Easton, A. S., and Abbott, N. J. (2002) Bradykinin increases permeability by calcium and 5-lipoxygenase in the ECV304/C6 cell culture model of the blood-brain barrier. Brain Res. 953, 157-169
58. Hu, T., Ramachandrarao, S. P., Siva, S., Valancius, C., Zhu, Y., Mahadev, K., Toh, I., Goldstein, B. J., Woolkalis, M., and Sharma, K. (2005) Reactive oxygen species production via NADPH oxidase mediates TGF-beta-induced cytoskeletal alterations in endothelial cells. Am. J. Physiol. Renal Physiol. 289, F816-F825
59. Belmont, H. M., Levartovsky, D., Goel, A., Amin, A., Giorno, R., Rediske, J., Skovron, M. L., and Abramson, S. B. (1997) Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthritis Rheum. 40, 1810-1816
60. Weinberg, J. B., Granger, D. L., Pisetsky, D. S., Seldin, M. F., Misukonis, M. A., Mason, S. N., Pippen, A. M., Ruiz, P., Wood, E. R., and Gilkeson, G. S. (1994) The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine. J. Exp. Med. 179, 651-660
61. Lossinsky, A. S., and Shivers, R. R. (2004) Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Review. Histol. Histopathol. 19, 535-564
62. Diamond, B., Kowal, C., Huerta, P. T., Aranow, C., Mackay, M., DeGiorgio, L. A., Lee, J., Triantafyllopoulou, A., Cohen-Solal, J., and Volpe, B. T. (2006) Immunity and acquired alterations in cognition and emotion: lessons from SLE. Adv. Immunol. 89, 289-320
63. Golombek, S. J., Graus, F., and Elkon, K. B. (1986) Autoantibodies in the cerebrospinal fluid of patients with systemic lupus erythematosus. Arthritis Rheum. 29, 1090-1097 (Pubitemid 16017799)
64. Abramson, S., Belmont, H. M., Hopkins, P., Buyon, J., Winchester, R., and Weissmann, G. (1987) Complement activation and vascular injury in systemic lupus erythematosus. J. Rheumatol. 14(Suppl. 13), 43-46 (Pubitemid 17118015)
65. Brey, R. L., Sakic, B., Szechtman, H., and Denburg, J. A. (1997) Animal models for nervous system disease in systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 823, 97-106
66. Kowal, C., DeGiorgio, L. A., Lee, J. Y., Edgar, M. A., Huerta, P. T., Volpe, B. T., and Diamond, B. (2006) Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc. Natl. Acad. Sci. U. S. A. 103, 19854-19859
67. Arora, V., Verma, J., Dutta, R., Marwah, V., Kumar, A., and Das, N. (2004) Reduced complement receptor 1 (CR1, CD35) transcription in systemic lupus erythematosus. Mol. Immunol. 41, 449-456
68. Jongen, P. J., Doesburg, W. H., Ibrahim-Stappers, J. L., Lemmens, W. A., Hommes, O. R., and Lamers, K. J. (2000) Cerebrospinal fluid C3 and C4 indexes in immunological disorders of the central nervous system. Acta Neurol. Scand. 101, 116-121
69. Bao, L., Osawe, I., Puri, T., Lambris, J. D., Haas, M., and Quigg, R. J. (2005) C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur. J. Immunol. 35, 2496-2506
70. Hu, T., Ramachandrarao, S. P., Siva, S., Valancius, C., Zhu, Y., Mahadev, K., Toh, I., Goldstein, B. J., Woolkalis, M., and Sharma, K. (2005) Reactive oxygen species production via NADPH oxidase mediates TGF-beta-induced cytoskeletal alterations in endothelial cells. Am. J. Physiol. Renal Physiol. 289, F816-F825
71. Brown, G. C., and Borutaite, V. (2006) Interactions between nitric oxide, oxygen, reactive oxygen species and reactive nitrogen species. Biochem. Soc. Trans. 34, 953-956
72. Guo, R. F., and Ward, P. A. (2005) Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23, 821-852
73. Hawlisch, H., Belkaid, Y., Baelder, R., Hildeman, D., Gerard, C., and Kohl, J. (2005) C5a negatively regulates toll-like receptor 4-induced immune responses. Immunity 22, 415-426
74. Pytel, P., and Alexander, J. J. (2009) Pathogenesis of septic encephalopathy. Curr. Opin. Neurol. 22, 283-287